Market Newsdesk

Nes-Ziona, Israel, March 08, 2021 (GLOBE NEWSWIRE) — Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “Company”), a clinical-stage macrophage reprogramming immunotherapy company targeting diseased macrophages in patients with sepsis, COVID-19 and solid tumors, today announced that the Japan Patent Office issued a notice of allowance for a new patent application (number 2017-543802) covering Allocetra^TM, the Company’s immunotherapy product candidate. Upon issuance, the patent, titled “Combination Immune Therapy and Cytokine Control Therapy for Cancer Treatment”, will provide added intellectual property protection in Japan with respect to certain methods, uses and pharmaceutical compositions for Allocetra^TM in combination with CAR-T therapies. The company expects that this new patent will be issued in Japan in the second quarter of 2021.

Enlivex is developing Allocetra^TM as a universal, off-the-shelf cell therapy designed to reprogram macrophages into their homeostatic state. Diseases such as solid cancers, sepsis, COVID-19 and many others reprogram macrophages out of their homeostatic state. These non-homeostatic macrophages contribute significantly to the severity of the respective diseases. By restoring macrophage homeostasis, Allocetra^TM has the potential to provide a novel immunotherapeutic mechanism of action for life-threatening clinical indications that are defined as “unmet medical needs”, as a stand-alone therapy or in combination with other therapeutic agents.

ABOUT ENLIVEX

Enlivex is a clinical stage macrophage reprogramming immunotherapy company developing Allocetra^TM, a universal, off-the-shelf cell therapy designed to reprogram macrophages into their homeostatic state. Resetting non-homeostatic macrophages into their homeostatic state is critical for immune system rebalancing and resolution of life-threatening conditions. For more information, visit http://www.enlivex.com.

Safe Harbor Statement:  This press release contains forward-looking statements, which may be identified by words such as “expects,” “plans,” “projects,” “will,” “may,” “anticipates,” “believes,” “should,” “would”, “could,” “intends,” “estimates,” “suggests,” “has the potential to” and other words of similar meaning, including statements regarding expected cash balances, market opportunities for the results of current clinical studies and preclinical experiments, the effectiveness of, and market opportunities for, ALLOCETRA^TM programs. All such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995.  Investors are cautioned that forward-looking statements involve risks and uncertainties that may affect Enlivex’s business and prospects, including the risks that Enlivex may not succeed in generating any revenues or developing any commercial products; that the products in development may fail, may not achieve the expected results or effectiveness and/or may not generate data that would support the approval or marketing of these products for the indications being studied or for other indications; that ongoing studies may not continue to show substantial or any activity; and other risks and uncertainties that may cause results to differ materially from those set forth in the forward-looking statements. The results of clinical trials in humans may produce results that differ significantly from the results of clinical and other trials in animals. The results of early-stage trials may differ significantly from the results of more developed, later-stage trials. The development of any products using the ALLOCETRA^TM product line could also be affected by a number of other factors, including unexpected safety, efficacy or manufacturing issues, additional time requirements for data analyses and decision making, the impact of pharmaceutical industry regulation, the impact of competitive products and pricing and the impact of patents and other proprietary rights held by competitors and other third parties.  In addition to the risk factors described above, investors should consider the economic, competitive, governmental, technological and other factors discussed in Enlivex’s filings with the Securities and Exchange Commission, including in the Company’s most recent Annual Report on Form 20-F filed with the Securities and Exchange Commission.  The forward-looking statements contained in this press release speak only as of the date the statements were made, and we do not undertake any obligation to update forward-looking statements, except as required under applicable law.

ENLIVEX CONTACT

Shachar Shlosberger, CFO
Enlivex Therapeutics, Ltd.
[email protected]

INVESTOR RELATIONS CONTACT

Eric Ribner
LifeSci Advisors
[email protected]

BASKING RIDGE, N.J., March 08, 2021 (GLOBE NEWSWIRE) — Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a clinical-stage biopharmaceutical company dedicated to the development of cellular therapies designed to reverse disease, today announced that the U.S. Food and Drug Administration (“FDA”) has granted orphan drug designation to the Company’s CD34+ cell therapy product, CLBS12, for the treatment of Buerger’s disease – also known as thromboangiitis obliterans – a condition related to critical limb ischemia (“CLI”) with no approved treatments to date in the U.S. .

“We are very pleased that the FDA has granted orphan drug designation to CLBS12 in Buerger’s disease. Without a currently approved or effective treatment for this condition in the U.S., a significant unmet need remains for therapies that slow, stop or, ideally, reverse this debilitating disease,” stated David J. Mazzo, Ph.D., President and Chief Executive Officer of Caladrius. “The Company’s ongoing open-label, registration-eligible study of HONEDRA® (CLBS12) as a treatment for CLI and Buerger’s Disease in Japan has shown strong results to date with approximately 60% of subjects in the completed Buerger’s Disease cohort reaching a positive ‘CLI-free’ endpoint despite the natural history of continuous disease progression leading to amputation. With this designation we can now engage FDA in discussions to define the most efficient and rapid development pathway to registration in the U.S. Achieving orphan designation for CLBS12 takes us one step closer to realizing our goal of fulfilling the unmet medical need for Buerger’s Disease patients around the world.”

Orphan drug designation is granted by the FDA’s Office of Orphan Products Development, which provides orphan status to drugs or biologics that are intended to treat rare diseases or disorders that affect fewer than 200,000 people in the United States. This designation provides the sponsor of the drug certain incentives, including tax credits, for qualified clinical trials and fee waivers. Orphan Drug designation confers eligibility for seven years of market exclusivity to an orphan drug post-approval, subject to a receipt by the FDA of marketing approval.

About Caladrius Biosciences

Caladrius Biosciences, Inc. is a clinical-stage biopharmaceutical company dedicated to the development of cellular therapies designed to reverse disease. We are developing first-in-class cell therapy products based on the finely tuned mechanisms for self-repair that exist in the human body. Our technology leverages and enables these mechanisms in the form of specific cells, using formulations and modes of delivery unique to each medical indication.

The Company’s current product candidates include: CLBS16, the subject of both a recently completed positive Phase 2a study and a newly initiated Phase 2b study in the U.S. for the treatment of coronary microvascular dysfunction (“CMD”); HONEDRA® (CLBS12), recipient of orphan designation for Buerger’s Disease in the U.S. as well as SAKIGAKE designation and eligible for early conditional approval in Japan for the treatment of critical limb ischemia (“CLI”) and Buerger’s Disease based on the results of an ongoing clinical trial; CLBS201, designed to assess the safety and efficacy of CD34+ cell therapy as a treatment for chronic kidney disease (“CKD”); and OLOGO™ (CLBS14), a Regenerative Medicine Advanced Therapy (“RMAT”) designated therapy for which the Company is in discussion with the FDA to finalize a Phase 3 protocol of reduced size and scope for a confirmatory trial in subjects with no-option refractory disabling angina (“NORDA”). For more information on the Company, please visit www.caladrius.com.

Contact:

Investors:
Caladrius Biosciences, Inc.
John Menditto
Vice President, Investor Relations and Corporate Communications
Phone: +1-908-842-0084
Email: [email protected]

Media:
W2O Group
Christiana Pascale
Phone: +1-212-257-6722
Email: [email protected]

HAUPPAUGE, N.Y., March 08, 2021 (GLOBE NEWSWIRE) — Chembio Diagnostics, Inc. (Nasdaq: CEMI), a leading point-of-care diagnostic company focused on infectious diseases, today announced the appointment of David Bespalko to the Company’s Board of Directors, effective upon his election on March 4, 2021.

Mr. Bespalko brings over 35 years of leadership experience in the global in vitro diagnostics market. Most recently he was Group Vice President, Global Commercial Operations Specialty Diagnostics Group at Thermo Fisher Scientific, which he joined in 2011 as President of Fisher Healthcare. During his tenure there, Mr. Bespalko held additional roles such as President of the Global Anatomical Pathology Division. Previously, Mr. Bespalko was Corporate Vice President, North America Commercial Operations at Beckman Coulter. His diagnostics career began in Canada with commercial and general management roles at Baxter Healthcare and Dade Behring. Mr. Bespalko now manages his own consulting firm, BMC, helping early-stage companies and providing executive mentorship.

Also on March 4, 2021, Dr. Mary Lake Polan informed the Board of Directors that she would not stand for reelection to the Board at the Company’s 2021 Annual Meeting of Shareholders.

“We are delighted to welcome David to the Board of Directors,” said Katherine L. Davis, Chair of Chembio’s Board of Directors. “Given David’s extensive network and experience in the industry, he will add valuable insight to help maximize the value of our DPP platform in the market. We look forward to his collaboration and contributions. We also would like to thank Dr. Polan for her service and leadership throughout her tenure and wish her well in her future endeavors.”

“I am excited about the opportunity to work with the Chembio team because they have an advanced point-of-care technology and a tremendous opportunity to provide value across decentralized settings in the healthcare landscape,” said Mr. Bespalko. “I am thrilled to join an organization whose mission aligns with my background, focused on expanding and scaling operations to enable greater access to diagnostic testing.”

About the DPP Rapid Test Platform

Chembio’s proprietary DPP technology platform provides high-quality, rapid diagnostic results in 15 to 20 minutes using a small drop of blood from the fingertip or alternative samples. Through advanced multiplexing, the DPP platform can detect up to eight, distinct test results from a single patient sample, delivering greater clinical value than other rapid tests. For certain applications, Chembio’s easy-to-use, highly portable, battery-operated DPP Micro Reader optical analyzer then reports accurate results in approximately 15 seconds, making it well-suited for decentralized testing where real-time results enable patients to be clinically assessed while they are still on-site. Objective results produced by the DPP Micro Reader reduce the possibility of the types of human error that can be experienced in the visual interpretations required by many rapid tests.

Chembio’s portfolio of DPP-based point-of-care tests with FDA regulatory approvals include the DPP HIV-Syphilis System (PMA approved), DPP HIV 1/2 Assay (PMA approved and CLIA waived), DPP Zika IgM System (510(k)), and DPP Ebola Antigen System (EUA). Additionally, DPP-based tests have received regulatory approvals from the World Health Organization, CE-Mark, Agência Nacional de Vigilância Sanitária (ANVISA), and other global organizations, where they aid in the detection and diagnosis of several other critical diseases and conditions.

All DPP tests are developed and manufactured in the United States and are the subject of a range of domestic and global patents and patents pending.

About Chembio Diagnostics

Chembio is a leading point-of-care diagnostics company focused on detecting and diagnosing infectious diseases, including COVID-19, sexually transmitted disease, and fever and tropical disease. Coupled with Chembio’s extensive scientific expertise, its novel DPP technology offers broad market applications beyond infectious disease. Chembio’s products are sold globally, directly and through distributors, to hospitals and clinics, physician offices, clinical laboratories, public health organizations, government agencies, and consumers. Learn more at www.chembio.com.

DPP is Chembio’s registered trademark, and the Chembio logo is Chembio’s trademark. For convenience, these trademarks appear in this release without ® or ™ symbols, but that practice does not mean that Chembio will not assert, to the fullest extent under applicable law, its rights to the trademark.

Contact:

Philip Taylor
Gilmartin Group
(415) 937-5406
[email protected] 

CHICO, Calif., March 08, 2021 (GLOBE NEWSWIRE) — Northern California National Bank (“NorCal” or the “Bank”) announced today the signing of an agreement pursuant to which investors will seek to acquire 100% of the shares of NorCal through a tender offer to all its stockholders. Pursuant to the agreement and subject to regulatory approval, the investors will offer $33.07 in cash for each share of NorCal common stock, which represents a 61% premium over the Bank’s closing price per share on March 5, 2021. Assuming all of the outstanding shares are tendered to the investors, the aggregate consideration to be paid the Bank’s shareholders will be approximately $50 million.

After the investor’s acquisition of the tendered shares, NorCal will continue to operate as Northern California National Bank and current Chief Executive Officer and President Todd Lewis will remain in an active leadership role with other members of NorCal’s senior management. Employees of NorCal will continue to support the financial needs of its customers and members of its community in the same manner as they have since the Bank’s inception in 2006.

“The Board of Directors of Northern California National Bank is very excited about the merits of this transaction,” said President and CEO Todd Lewis. “It’s a unique opportunity to provide compelling value to our shareholders while continuing to deliver our customers exceptional service without any disruption. The acquiring investors are committed to maintaining the Bank’s high quality customer service with a long-term view that prioritizes the Bank’s positive contribution to the Chico community.”

The proposed transaction is subject to the tendering of at least 67% of the outstanding shares held by NorCal shareholders as well as required regulatory approval and other conditions specified in the agreement. The transaction is expected to close in the second half of 2021.

Piper Sandler & Co. acted as financial advisor to NorCal and delivered a fairness opinion to the Board of Directors of NorCal. Kirton McConkie, PC and Manatt, Phelps & Phillips, LLP served as legal counsel to NorCal. Hovde Group, LLC acted as financial advisor to the investors. Luse Gorman, PC served as legal counsel to the investors.

About Northern California National Bank

Located at the corner of 7th Avenue and Mangrove, Northern California National Bank is a locally owned and operated bank servicing the needs of the businesses and individuals in Northern California since March 2006. The Bank has a full service branch in Chico, CA and a Loan Production Office in Sacramento, CA. For more information call (530) 879-5900 or visit the website at www.norcalbank.com.

Forward-Looking Statements

Statements made in this release, other than those concerning historical financial information, may be considered forward-looking statements within the meaning of Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by the fact that they do not relate strictly to historical or current facts. They often include words such as “believe,” “expect,” “anticipate,” “intend,” “plan,” “estimate,” “aim,” “projects,” or words of similar meaning and expressions that indicate future events and trends, or future or conditional verbs such as “will,” “would,” “should,” “could,” or “may” or the negative of such terms or expressions. Such statements speak only as of the date of this release and are based on current expectations and involve a number of assumptions. These include statements as to the anticipated benefits of the transaction, including future operating and business plans, as well as other statements of expectations. The Bank’s ability to predict results, or the actual effect of the transaction, including future plans, expectations or strategies, is inherently uncertain. Factors which could have a material effect on the operations and future prospects of the Bank and the ability to consummate the transactions contemplated by the acquisition agreement, include but are not limited to: (1) customer and employee relationships and business operations may be disrupted by the transaction; (2) the ability to obtain required regulatory approvals and meet the conditions set forth in the acquisition agreement, including conditions relating to a minimum percentage of tendered shares, may be more difficult, time-consuming or costly than expected and may not be obtained at all; and (3) changes in interest rates, general economic conditions, challenges posed by the Covid-19 pandemic, legislative/regulatory changes, monetary and fiscal policies of the U.S. government, including policies of the U.S. Treasury and the Board of Governors of the Federal Reserve; the quality and composition of the loan and securities portfolios; demand for loan products; deposit flows; competition; demand for financial services in the Bank’s market area; implementation of new technologies; ability to develop and maintain secure and reliable electronic systems; and accounting principles, policies, and guidelines may adversely effect the Bank’s current and future operations. The Bank undertakes no obligation to update or clarify these forward-looking statements, whether as a result of new information, future events or otherwise except as otherwise required by law.

For additional information or questions, please contact:

Todd Lewis

President/CEO

Northern California National Bank
(530) 899-4214

Dubbed “the highest-profile media lawyer in America” by The Hollywood Reporter, and “Hollywood’s favorite lawyer,” by Financial Times, CHARLES HARDER gives readers an inside look at his most famous celebrity cases during his 25-year career.

NEW YORK, March 08, 2021 (GLOBE NEWSWIRE) — Coinciding with the fifth anniversary of the landmark $140 million jury verdict for Hulk Hogan that forced Gawker Media into bankruptcy, powerhouse attorney CHARLES HARDER tells his story for the first time with the release of GAWKER SLAYER: The Professional and Personal Adventures of Famed Attorney CHARLES HARDER.

Gawker Slayer intertwines fascinating narrations of Harder’s biggest cases, with personal stories about his life, upbringing and legal career, with commentary on the media, law and major topics of the times, including media bias, journalistic ethics, and cancel culture.

Gawker Slayer includes in-depth discussion of the following cases, among others:

• A multi-chapter look inside the legal battle between Hulk Hogan and Gawker Media which put the company out of business.
• Winning a multi-million-dollar settlement, plus full retraction and apology, for First Lady Melania Trump against the Daily Mail.
• Beating Stormy Daniels in two federal lawsuits, on behalf of client President Trump.
• Representing Amber Heard in her divorce case against ex-husband Johnny Depp.
• Representing Halle Berry in rewriting California harassment laws to protect children from the paparazzi.
• Representing the Julia Child Foundation against Thermador for posthumously using her name and image to market their products without permission.
• Representing Sandra Bullock, Cameron Diaz and Reese Witherspoon in lawsuits to protect their name and image rights.

“Gawker Slayer is about doing what’s necessary, sometimes through extraordinary measures, to protect fundamental rights, including free speech and free expression,” says Harder, “and protect individuals against the excesses of powerful media corporations, and promote responsibility and civility in society.”

Gawker Slayer is available internationally in Paperback (US$18.00) and e-book (US$9.99) on Amazon.

ABOUT CHARLES HARDER:

Dubbed “the highest-profile media lawyer in America” by The Hollywood Reporter, “Hollywood’s favorite lawyer,” by Financial Times, and awarded the California Lawyer of the Year, Media (CLAY award) in 2017, Charles Harder is a U.S. litigation and trial attorney who specializes media law, First Amendment, defamation, privacy, reputation protection, entertainment, intellectual property and business litigation. He is founder and managing partner of HARDER LLP (www.HarderLLP.com) based in Los Angeles, with offices in New York.

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/933033c7-18db-4686-b030-36a57150ad50

MEDIA CONTACTS:
Samantha Perriello
[email protected]
585-727-0991

Anna Walsh
[email protected]
917-969-7081

EDISON, N.J., March 08, 2021 (GLOBE NEWSWIRE) — StrikeForce Technologies, Inc. (OTC PINK: SFOR), a cyber technology company that prevents data theft and security breaches, today announced the global commercial launch of SafeVchat, the first video conferencing platform designed with a cybersecurity kernel and engineered to secure enterprise communications and keep privacy intact.

With the workforce shifting to remote over the past year, due to the pandemic, the business world has become reliant on video conferencing as a replacement to in-person meetings. While existing video conferencing platforms have been a convenient means of communication, the stark reality is that they were not built with security as a priority or even a consideration. According to research from Blind Report, over a third of working professionals are worried their information may have been compromised on Zoom.

“With countless reports of ‘Zoom bombings’ and other video conferencing-related cyber-attacks, the launch of this new service comes at a crucial juncture where we’ve grown more dependent than we could have imagined on these unsecure platforms,” said Steve Cooper, former CIO, U.S. Department of Commerce, the Federal Aviation Administration, the U.S. Department of Homeland Security, and Advisory Board Chairman for StrikeForce. “Video conferencing is here to stay, and SafeVchat offers a secure option that will become an essential tool for any organization looking to confidently keep both their own, and their customer data safe while maintaining complete compliance.”

SafeVchat, a client-less, web, and mobile-based video conferencing platform is designed to protect users from the common attacks and threats that leverage existing platforms as a vehicle to distribute malware. Platforms like Zoom, MS Teams, WebEx and others have proven time and again to be vulnerable to cyber-attacks. SafeVchat’s signature five-level security approach includes a strict password-protected meeting invitation system that encompasses multi-factor authentication, ensuring only pre-approved users can attend a meeting. Additionally, all meeting endpoints are secured from potential malware attacks, and all audio and video are encrypted.

“SafeVchat was built to fill a crucial gap in the video conferencing market, balancing between user-friendly video communication and top-of-the-line security,” said Mark L. Kay, CEO, StrikeForce Technologies. “Since we announced the controlled rollout of the product in late December, we’ve already signed hundreds of customers and 14 international resellers. This early interest is proof that most professional industries, including financial services, insurance, government and education are unhappy with the lax security of their current services and are looking for better and more secure alternatives.”

Every day a new “Zoom bomb” attack makes the news and a private meeting is invaded by unwanted guests. While these disruptions are oftentimes smaller nuisances, it’s just the tip of the iceberg when it comes to the much more serious security issues facing governments and larger enterprises. SafeVchat was designed to make video conversations fully secure, ensuring that businesses aren’t putting themselves at risk for attack during meetings.

“In this new remote work environment, our employees and customers need to frequently connect in a privacy safe manner in order to conduct business and discuss strategies and visions,” said Heath Colvin, Director of Sales and Marketing, FSTI, Inc., a leading supplier to the Oil & Gas industry. “Virtual meetings have become the new normal in our field, however, many of these widely used services are insecure, which can lead to sensitive information being exposed or put at risk. SafeVchat is the only product on the market we’ve seen that guarantees secure two-factor authentication for every user meeting participant, which is vital for our businesses in terms of preventing breaches and keeping customers and teams protected.”

Additional, new features SafeVchat features that have been implemented since December’s soft rollout include:

• Multiple Authentication Methods – SafeVchat includes eight different authentication methods, including fingerprint biometrics, with facial recognition capabilities to be released-soon
• Authentication Determined By Host – Meeting managers can select which types of authentication method each participant may use
• Analytics and Reporting – SafeVchat provides comprehensive analytics reporting that enables granular level detailed reports about every meeting
• Unmatched Compliance
  – SafeVchat meets all cybersecurity compliance protocols, including GDPR, PCI-DSS, HIPPA, CCPA, SOX, NYDFS, etc.

A mobile version of SafeVchat is available for download on both the Google Play store and Apple’s App Store.

For more information and to purchase SafeVchat, please visit https://www.safevchat.com.

About StrikeForce Technologies, Inc.

StrikeForce Technologies helps to prevent Cyber theft and data security breaches for consumers, corporations, and government agencies. It provides powerful two-factor, “Out-of-Band” authentication and keystroke encryption along with mobile solutions. StrikeForce Technologies, Inc. (OTC PINK:SFOR) is headquartered in Edison, N.J., and can be reached at www.strikeforcetech.com or by phone at (732) 661-9641 or toll-free at (866) 787-4542.

Safe Harbor Statement:

Matters discussed in this press release contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. When used in this press release, the words “anticipate,” “believe,” “estimate,” “may,” “intend,” “expect” and similar expressions identify such forward-looking statements. Actual results, performance or achievements could differ materially from those contemplated, expressed or implied by the forward-looking statements contained herein. These forward-looking statements are based largely on the expectations of the Company and are subject to a number of risks and uncertainties. These include, but are not limited to, risks and uncertainties associated with: the sales of the company’s identity protection software products into various channels and market sectors, the impact of COVID-19, the issuance of the company’s pending patent application, and the impact of economic, competitive and other factors affecting the Company and its operations, markets, product, and distributor performance, the impact on the national and local economies resulting from terrorist actions, and U.S. actions subsequently; and other factors detailed in reports filed by the company.

Media Contact Info:

Fusion Public Relations, on behalf of SafeVChat:

Olga Shmuklyer
917.715.0329
[email protected]

RICHMOND, Va., March 08, 2021 (GLOBE NEWSWIRE) — CarLotz (NASDAQ: LOTZ), the nation’s largest consignment-to-retail used vehicle marketplace, announced today it will open its first Tennessee hub in the coming weeks. The Nashville-area hub, located at 1821 Gallatin Pike N. in Madison, TN, is expected to open by the end of March.

CarLotz is on a mission to create the world’s greatest vehicle buying and selling experience for customers. “CarLotz’ consignment model is a category leader and our guests are responding,” said Michael Bor, Co-Founder and Chief Executive Officer of CarLotz. “Nashville is an exciting city and a meaningful milestone in our ambitious growth plan. We firmly believe the great people of Tennessee will be thrilled to get more money for their car and more car for their money. We can’t wait to open up and show our new guests what we’re all about.” Bor continued, “Nashville’s strong growth, vibrant community, and location are complementary to CarLotz’ other southeast US locations, and make this a perfect next step as we execute on our mission to spread the unique CarLotz model across the US.”

Tennessee marks the ninth southeast US opening for CarLotz and 11^th nationwide, adding to its hubs in Virginia, North Carolina, Florida, Illinois and Texas. In addition, the Company recently opened its first west coast hub in Seattle, Washington, further expanding its full omni-channel offering.

CarLotz is hiring for sales coaches, service techs, managers and other roles at the new Nashville location. To learn more and apply, visit www.carlotz.com/careers or reach out to [email protected]

For additional information, visit carlotz.com 

About CarLotz 
CarLotz is a used vehicle consignment and Retail Remarketing™ business that provides our corporate vehicle sourcing partners and retail sellers of used vehicles with the ability to access the previously unavailable retail sales channel, while simultaneously providing buyers with prices that are, on average, below those of traditional dealerships. Our mission is to create the world’s greatest vehicle buying and selling experience. We operate a technology-enabled buying, sourcing and selling model that offers a seamless omni-channel experience and comprehensive selection of vehicles, while allowing for a fully contactless end-to-end e-commerce interface that enables no hassle buying and selling. Our proprietary Retail Remarketing™ technology provides our corporate vehicle sourcing partners with real-time performance metrics and data analytics, along with custom business intelligence reporting that enables price and vehicle triage optimization between the wholesale and retail channel. Through our marketplace model, we generate significant value for both sellers and buyers through price, selection and experience. 

Investor Contact:

[email protected]

HOUSTON, March 08, 2021 (GLOBE NEWSWIRE) — Sysco Corporation (NYSE:SYY), the leading global foodservice distribution company, today announced the Company’s third annual observance of International Women’s Day (IWD) across its global organization. 

“Sysco is proud to celebrate International Women’s Day as part of our commitment to diversity, equity and inclusiveness,” said Kevin Hourican, Sysco’s president and CEO. “It’s an important opportunity for Sysco associates around the world to rally together and reinforce the significance of gender equality and support for all women.” 

This year’s campaign theme, Choose To Challenge, emphasizes that a challenged world is an alert world, and from challenge comes change.

A cross-functional steering committee of women leaders and over 30 volunteers from across the organization led the Company’s efforts to encourage Sysco associates to challenge stereotypes, fight biases and broaden perceptions in their workplaces and the broader foodservice industry.  

As part of the Company’s celebration, Sysco held its annual panel discussion on Tuesday, March 2. Every year, this event features a panel of Sysco’s women leaders and associates discussing current challenges to gender equality and how to address and overcome those challenges. More than 6,500 associates attended the virtual discussion, which was streamed live and accessible to all Sysco associates around the world.

In addition to a variety of celebrations around the globe, Sysco will also honor winners of its Gender Equity Momentum (GEM) Award on March 8. The GEM Award recognizes associates who are making strides to remove gender barriers, champion gender equality and cultivate an inclusive culture.

For more information on Sysco’s commitment to diversity, equity and inclusion, visit sysco.com.  

About Sysco


Sysco is the global leader in selling, marketing and distributing food products to restaurants, healthcare and educational facilities, lodging establishments and other customers who prepare meals away from home. Its family of products also includes equipment and supplies for the foodservice and hospitality industries. With more than 57,000 associates, the company operates 326 distribution facilities worldwide and serves more than 625,000 customer locations. For fiscal 2020 that ended June 27, 2020, the company generated sales of more than $52 billion. Information about our CSR program, including Sysco’s 2020 Corporate Social Responsibility Report, can be found at www.sysco.com/csr2020report.

For more information, visit www.sysco.com or connect with Sysco on Facebook at www.facebook.com/SyscoCorporation or Twitter at https://twitter.com/Sysco. For important news and information regarding Sysco, visit the Investor Relations section of the company’s Internet home page at www.investors.sysco.com which Sysco plans to use as a primary channel for publishing key information to its investors, some of which may contain material and previously non-public information. In addition, investors should continue to review our news releases and filings with the SEC. It is possible that the information we disclose through any of these channels of distribution could be deemed to be material information. 

For more information contact:

Shannon Mutschler
Media Contact
[email protected] 
T 281-584-4059

 

REDWOOD CITY, Calif., March 08, 2021 (GLOBE NEWSWIRE) — Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today provided an update following recent interactions with the U.S. Food and Drug Administration (FDA) regarding the development of once-daily DCCR (diazoxide choline) extended release tablets for the treatment of Prader-Willi Syndrome (PWS).

Subsequent to the previously disclosed Type C meeting with the FDA on November 12, 2020 regarding the potential adequacy of data from studies with DCCR to support a New Drug Application (NDA) for the treatment of PWS, Soleno submitted additional analyses to the FDA from the Company’s Phase 3 trial, DESTINY PWS (C601). These data were from study visits that were completed prior to the significant disruptions caused by the COVID-19 pandemic. The data analyses showed statistically significant changes for DCCR compared to placebo in the primary and key secondary endpoints. Following its review of the data submitted by Soleno, the FDA informed the Company on March 5, 2021 that an additional controlled clinical trial will be necessary to support an NDA submission for DCCR in PWS.

“We intend to continue the dialogue with the FDA to ensure that DCCR is approved for individuals with PWS as expeditiously as possible,” said Anish Bhatnagar, M.D., Chief Executive Officer of Soleno Therapeutics. “Based on the totality of data generated to date, we remain confident in DCCR’s potential to address the unmet need for a safe and effective treatment option for PWS patients. We are currently evaluating the appropriate next steps for our DCCR program.”

About PWS

The Prader-Willi Syndrome Association USA estimates that PWS occurs in one in every 15,000 live births in the U.S. The hallmark symptom of this disorder is hyperphagia, a chronic feeling of insatiable hunger that severely diminishes the quality of life for PWS patients and their families. Additional characteristics of PWS include behavioral problems, cognitive disabilities, low muscle tone, short stature (when not treated with growth hormone), the accumulation of excess body fat, developmental delays, and incomplete sexual development. Hyperphagia can lead to significant morbidities (e.g., obesity, diabetes, cardiovascular disease) and mortality (e.g., stomach rupture, choking, accidental death due to food seeking behavior). In a global survey conducted by the Foundation for Prader-Willi Research, 96.5% of respondents (parent and caregivers) rated hyperphagia as the most important or a very important symptom to be relieved by a new medicine. There are currently no approved therapies to treat the hyperphagia/appetite, metabolic, cognitive function, or behavioral aspects of the disorder. Diazoxide choline has received Orphan Drug Designation for the treatment of PWS in the U.S. and EU, and Fast Track Designation in the U.S.

About DCCR (Diazoxide Choline) Extended-Release Tablets

DCCR is a novel, proprietary extended-release dosage form containing the crystalline salt of diazoxide and is administered once-daily. The parent molecule, diazoxide, has been used for decades in thousands of patients in a few rare diseases in neonates, infants, children and adults, but has not been approved for use in PWS. Soleno conceived of and established extensive patent protection on the therapeutic use of diazoxide and DCCR in patients with PWS. The DCCR development program is supported by data from five completed Phase 1 clinical studies in healthy volunteers and three completed Phase 2 clinical studies, one of which was in PWS patients. In the PWS Phase 3 study, DCCR showed promise in addressing hyperphagia, the hallmark symptom of PWS, as well as several other symptoms such as aggressive/destructive behaviors, fat mass and other metabolic parameters.

About Soleno Therapeutics, Inc.

Soleno is focused on the development and commercialization of novel therapeutics for the treatment of rare diseases. The company’s lead candidate, DCCR extended-release tablets, a once-daily oral tablet for the treatment of Prader-Willi Syndrome (PWS), is currently being evaluated in a Phase 3 clinical development program. For more information, please visit www.soleno.life.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended. All statements other than statements of historical facts contained in this press release are forward-looking statements, including statements regarding timing of any regulatory process or ultimate approvals and determining a path forward for DCCR for the treatment of PWS. In some cases, you can identify forward-looking statements by terms such as “may,” “will,” “should,” “expect,” “plan,” “anticipate,” “could,” “intend,” “target,” “project,” “contemplates,” “believes,” “estimates,” “predicts,” “potential” or “continue” or the negative of these terms or other similar expressions. These forward-looking statements speak only as of the date of this press release and are subject to a number of risks, uncertainties and assumptions, including the risks and uncertainties associated with market conditions, as well as risks and uncertainties inherent in Soleno’s business, including those described in the company’s prior press releases and in the periodic reports it files with the SEC. The events and circumstances reflected in the company’s forward-looking statements may not be achieved or occur and actual results could differ materially from those projected in the forward-looking statements. Except as required by applicable law, the company does not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise.

Corporate Contact:

Brian Ritchie
LifeSci Advisors, LLC
212-915-2578

TORONTO, March 08, 2021 (GLOBE NEWSWIRE) — Decklar Resources Inc. (DKL-TSX Venture)(the “Company” or “Decklar”) is pleased to announce that it has completed a second and final closing of the Company’s previously announced private placement financing. The total gross proceeds raised by the private placement is CAD $4,722,400 and funds from this financing will be used to immediately advance operational activities to re-enter the Oza-1 well at the Oza Oil Field in Nigeria and for general corporate purposes. Funds from this private placement are expected to be sufficient to re-enter the Oza-1 well and to re-establish oil production at the Oza Oil Field through the Company’s wholly-owned Nigeria-based subsidiary, Decklar Petroleum Limited.

Final Closing of Private Placement of Common Shares

The Company has completed a private placement in which an aggregate of 16,865,714 Decklar common shares have been issued at a price of CAD $0.28 per share for total gross proceeds of CAD $4,722,400. The common shares to be issued as a result of this private placement will be subject to a four-month trading restriction. The second closing of the private placement has been completed whereby 2,595,714 common shares were issued at a price of CAD $0.28 per share for total gross proceeds of CAD $726,800. After issuance of the common shares from the closing of the private placement (including the common shares issued as finder’s fees in respect of the first closing), the Company will have total outstanding shares of 71,575,487. The private placement has been conditionally approved by the TSX Venture Exchange and is subject to final approval.

For further information:

Duncan T. Blount
Chief Executive Officer  Telephone: +1 305 890 6516
Email: [email protected]

David Halpin
VP Finance, Decklar Petroleum  Telephone: +1 403 816 3029
Email:[email protected]

Investor Relations: [email protected]

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Cautionary Language

Certain statements made and information contained herein constitute “forward-looking information” (within the meaning of applicable Canadian securities legislation). All statements in this news release, other than statements of historical facts, are forward-looking statements. Such statements and information (together, “forward looking statements”) relate to future events or the Company’s future performance, business prospects or opportunities.

All statements other than statements of historical fact may be forward-looking statements. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, assumptions or future events or performance (often, but not always, using words or phrases such as “seek”, “anticipate”, “plan”, “continue”, “estimate”, “expect, “may”, “will”, “project”, “predict”, “potential”, “targeting”, “intend”, “could”, “might”, “should”, “believe” and similar expressions) are not statements of historical fact and may be “forward-looking statements”. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause actual results or events to differ materially from those anticipated in such forward-looking statements. The Company believes that the expectations reflected in those forward-looking statements are reasonable, but no assurance can be given that these expectations will prove to be correct and such forward-looking statements should not be unduly relied upon. The Company does not intend, and does not assume any obligation, to update these forward-looking statements, except as required by applicable laws. These forward-looking statements involve risks and uncertainties relating to, among other things, changes in oil prices, results of exploration and development activities, uninsured risks, regulatory changes, defects in title, availability of materials and equipment, timeliness of government or other regulatory approvals, actual performance of facilities, availability of financing on reasonable terms, availability of third party service providers, equipment and processes relative to specifications and expectations and unanticipated environmental impacts on operations. Actual results may differ materially from those expressed or implied by such forward-looking statements.

The Company provides no assurance that forward-looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking statements. The Company does not assume the obligation to revise or update these forward-looking statements after the date of this document or to revise them to reflect the occurrence of future unanticipated events, except as may be required under applicable securities laws.